Pertuzumab Plus High-Dose Trastuzumab Induces Clinical Benefit in HER2+ Metastatic Breast Cancer With CNS Metastases
Despite a modest central nervous system overall response rate, the combination of pertuzumab and high-dose trastuzumab was found to induce clinical benefit in 68% of patients with HER2-positive metastatic breast cancer enrolled to the phase 2 PATRICIA trial.